Gene Therapy Market Growth Through 2030 Creates New Strategic Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Gene Therapy Market Revenue Outlook: What CAGR Is Expected Through 2030?
The gene therapy market has experienced explosive expansion in recent years, with its value projected to increase from $16.36 billion in 2025 to $21.46 billion in 2026, representing a compound annual growth rate (CAGR) of 31.2%. This historic growth has been driven by the rising incidence of genetic disorders, progress in viral vector technologies, heightened research and development expenditure in gene therapy, favorable government regulations, and greater public awareness of rare diseases.
The gene therapy sector is projected to undergo significant expansion in the coming years. By 2030, its value is anticipated to reach $35.61 billion, reflecting a compound annual growth rate (CAGR) of 13.5%. This forecasted growth is driven by factors such as the rise of personalized medicine, the emergence of CRISPR and gene editing therapies, increased funding from both public and private sources, the integration of artificial intelligence in gene therapy research, and a rise in collaborative international clinical trials. Key trends shaping this period include the development of tailored gene therapies, the widespread adoption of CRISPR and gene editing techniques, the evolution of regulatory and ethical frameworks, innovations in advanced viral and non-viral vectors, and an uptick in joint research efforts and clinical trials.
Download A Free Sample Report For Comprehensive Market Insights:
Gene Therapy Market Development Factors: Which Trends Are Supporting Demand?
The projected growth of the gene therapy market is being fueled by the increase in healthcare industry investments. Healthcare industry investment refers to the deployment of capital into firms that deliver medical services, produce medical devices or pharmaceuticals, provide health insurance, or support the healthcare sector in other ways. Such investment is instrumental in the gene therapy field, as many pharmaceutical companies are channeling funds into expanding their patent holdings and forging advantageous collaborations. Strategic capital infusion also facilitates the creation of cutting-edge gene therapy solutions. For example, the American Medical Association, a professional body in the United States, reported in April 2025 that U.S. healthcare spending in 2023 rose by 7.5% to reach $4.9 trillion, equating to $14,570 per person, surpassing the 4.6% growth recorded in 2022. Hence, the escalating investments in the healthcare sector are propelling the expansion of the gene therapy market.
Gene Therapy Market Segment Analysis: What Are The Major Market Categories?
The gene therapy market covered in this report is segmented –
1) By Gene Therapy Type: Germline Therapy, Somatic Cell Therapy
2) By Vector: Viral Vector, Non-Viral Vector
3) By Application: Oncology, Orphan Disease, Knee Osteoarthritis, Neurological Disorders
4) By End Users: Biopharmaceutical Companies, Research Institutes, Other End Users
Subsegments:
1) By Germline Therapy: Inherited Disease Treatment, Genetic Modification Of Embryos, Gene Editing Techniques, Ethical And Regulatory Considerations
2) By Somatic Cell Therapy: Cancer Gene Therapy, Monogenic Disorder Treatment, Gene Replacement Therapy, RNA-Based Therapies, Gene Editing Techniques
Gene Therapy Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the gene therapy market are concentrating their efforts on creating sophisticated products, particularly adeno-associated virus (AAV) vectors, aimed at improving the accuracy and efficiency of gene delivery for managing a range of hereditary conditions. AAV vectors are commonly employed in gene therapy as a means to transport genetic material into target cells. As an example, in April 2024, Pfizer Inc., a global biopharmaceutical firm headquartered in the United States, secured clearance from the Food and Drug Administration (FDA), a U.S. federal entity dedicated to safeguarding public health, for BEQVEZ (fidanacogene elaparvovec-dzkt). This gene therapy is designed for the treatment of adults diagnosed with moderate to severe hemophilia B, a genetic disorder that causes bleeding problems. The condition arises from a shortage of clotting factor IX (FIX), which makes individuals prone to excessive bleeding. BEQVEZ uses an AAV vector to introduce a working version of the FIX gene directly into liver cells, enabling the body to naturally produce this essential clotting protein.
Gene Therapy Market Leading Companies Driving Competitive Growth
Major companies operating in the gene therapy market are UniQure NV, REGENXBIO Inc., Bristol-Myers Squibb, BioMarin Pharmaceuticals Inc., Jazz Pharmaceuticals Inc., Biocon, EdiGene Inc, Takeda Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma, Merck, Lonza, Pfizer, Cellular Biomedicine Group, GenScript, Albumedix Ltd, Catalent, Freeline Therapeutics, DiNAQOR AG, Vivet Therapeutics, Allergan, Amgen, Biocad, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bayer AG, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio, Regen BioPharma, Bellicum, BrainStorm Cell Therapeutics, Pluristem, Sanofi
Access The Complete Gene Therapy Market Report:
Gene Therapy Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the gene therapy market in 2025. The regions covered in the gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
